Patten & Patten Inc. TN Reduces Stock Position in Merck & Co., Inc. $MRK

Patten & Patten Inc. TN lessened its holdings in Merck & Co., Inc. (NYSE:MRK) by 7.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 101,425 shares of the company’s stock after selling 7,763 shares during the quarter. Patten & Patten Inc. TN’s holdings in Merck & Co., Inc. were worth $10,676,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Lighthouse Financial Services Inc. ADV purchased a new position in Merck & Co., Inc. in the fourth quarter valued at $1,024,000. Baker Boyer National Bank purchased a new position in Merck & Co., Inc. in the fourth quarter valued at $325,000. Chesapeake Wealth Management increased its holdings in Merck & Co., Inc. by 0.6% in the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after buying an additional 87 shares during the last quarter. Van Strum & Towne Inc. increased its holdings in Merck & Co., Inc. by 24.6% in the fourth quarter. Van Strum & Towne Inc. now owns 13,293 shares of the company’s stock valued at $1,399,000 after buying an additional 2,625 shares during the last quarter. Finally, Strategic Wealth Advisors LLC acquired a new position in Merck & Co., Inc. in the fourth quarter valued at $595,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Activity

In other news, EVP Jennifer Zachary sold 121,573 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the sale, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Chirfi Guindo sold 10,000 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the sale, the chief marketing officer owned 70,615 shares of the company’s stock, valued at $8,361,522.15. This trade represents a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.17% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on MRK shares. Weiss Ratings restated a “hold (c+)” rating on shares of Merck & Co., Inc. in a research note on Friday, May 1st. JPMorgan Chase & Co. upped their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research note on Monday, April 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research note on Friday, February 13th. Citigroup started coverage on shares of Merck & Co., Inc. in a research note on Wednesday. They issued a “neutral” rating and a $125.00 price objective for the company. Finally, Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a landmark Science paper on a new large-scale biocatalytic synthesis method for its investigational oral PCSK9 inhibitor, enlicitide decanoate. The work supports manufacturing scalability for a potential future cardiovascular drug and underscores progress in Merck’s pipeline. Article Title
• Positive Sentiment: Merck also became the sole testing provider for Genetix Biotherapeutics’ FDA-approved gene therapies under a five-year agreement, strengthening its BioReliance services business and adding a recurring commercialization-related revenue stream. Article Title
• Neutral Sentiment: Analyst commentary highlighted Merck as a well-prepared dividend stock despite its upcoming patent cliff, suggesting the market is still weighing long-term earnings durability rather than reacting to a single catalyst. Article Title
• Negative Sentiment: Merck is heading toward a July 27 trial over Gardasil safety claims after the vaccine reached an $8.9 billion sales peak. The litigation risk could weigh on sentiment around one of Merck’s key growth franchises, even though the company continues to defend the product’s safety record. Article Title

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $111.26 on Friday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.30. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14. The company has a market capitalization of $274.78 billion, a PE ratio of 31.34, a P/E/G ratio of 2.53 and a beta of 0.18. The company has a fifty day moving average of $117.07 and a two-hundred day moving average of $108.31.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the firm earned $2.22 earnings per share. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.